Abstract:Objective: The tumor microenvironment plays a critical role in the radiotherapy and immunotherapy response of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Radioresistance is a key factor in treatment failure among patients who receive radical radiotherapy. Thus, new immune-related biomarkers associated with radiotherapy response in CESC are needed. Methods: In this study, the CIBERSORT and ESTIMATE methods were applied to determine the percentage of tumor-infiltrating cells and the number of immune components in 103 CESCs treated with radiotherapy from The Cancer Genome Atlas (TCGA) database. The main dysregulated genes were subjected to multivariate and univariate analyses. The prognostic value of this system was studied via receiver operating characteristic curve and survival analysis. For further confirmation, the biomarkers' expression levels and predictive value were validated by immunohistochemistry (IHC) and qRT-PCR. The CIBERSORT algorithm was used to calculate the compositional patterns of 22 types of immune cells in cervical cancer patients treated with radiation therapy. Results: Data for 17 radioresistant and 86 radiosensitive tumors were obtained from the The Cancer Genome Atlas database. 53 immune-related DEGs were identified. GO and KEGG analyses revealed that the DEGs were enriched in protein kinase B signaling, growth factors in cytokines, the MAPK pathway and the PI3K-Akt pathway. Then, 14 key immune-related genes built a risk scoring model were deemed prognostic in CESC with radiotherapy. The area under the curve (AUC) of the model was 0.723, and the high-risk group presented worse outcomes than the low-risk group. In addition, the high-risk group tended to have persistent tumors (p = 0.001). The high expression of WT1 and SPOUYT4 were associated with relapse, the high expression of Angiotensinogen and MIEN1 were associated with nonrelapse. Analysis of the immune microenvironment indicated that M0 macrophages, M2 macrophages, activated mast cells and resting memory CD4+ T cells were positively correlated with the risk score (p < 0.05). Conclusion: The novel immune-related risk scoring system has some advantages in predicting the prognosis and treatment response of cervical cancer patients treated with radiotherapy. Moreover, it might provide novel clues for providing targeted immune therapy to these patients.

A network approach to quantifying radiotherapy effect on cancer: Radiosensitive gene group centrality

Identification of Prognostic Biomarkers for Response to Radiotherapy by DNA Microarray in Nasopharyngeal Carcinoma Patients

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis

Predicting Response to Radiotherapy in Tumors with PET/CT: when and How?

Combining Network Topology with Transcriptomic Data for Identifying Radiosensitive Gene Signatures.

Prediction of Response to Radiotherapy by Characterizing the Transcriptomic Features in Clinical Tumor Samples Across 15 Cancer Types

Predicting radiotherapy efficacy and prognosis in tongue squamous cell carcinoma through an in-depth analysis of a radiosensitivity gene signature

Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.

A Multiple Genomic Data Fused SF2 Prediction Model, Signature Identification, and Gene Regulatory Network Inference for Personalized Radiotherapy

Radiosensitivity-Specific Proteomic and Signaling Pathway Network of Non-Small Cell Lung Cancer (NSCLC).

Development and validation of a radiosensitivity model to evaluate radiotherapy benefits in pan‐cancer

A novel immune-related risk-scoring system associated with the prognosis and response of cervical cancer patients treated with radiation therapy

Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics

Integrating Radiosensitive Genes Improves Prediction of Radiosensitivity or Radioresistance in Patients with Oesophageal Cancer

A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation

A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients

Radiosensitivity-Related Genes and Clinical Characteristics of Nasopharyngeal Carcinoma

Integrating Radiosensitivity Gene Signature Improves Glioma Outcome and Radiotherapy Response Prediction

Effect of radiotherapy on head and neck cancer tissues in patients receiving radiotherapy: a bioinformatics analysis-based study

An 11-Gene Signature Based on Treatment Responsiveness Predicts Radiation Therapy Survival Benefit Among Breast Cancer Patients

Prediction of Radiosensitive Patients with Gastric Cancer by Developing Gene Signature.